ICON PLC (ICLR)
IE0005711209 - Common Stock
Overall ICLR gets a fundamental rating of 5 out of 10. We evaluated ICLR against 59 industry peers in the Life Sciences Tools & Services industry. ICLR has an average financial health and profitability rating. ICLR is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
ICLR had positive earnings in the past year.
ICLR had a positive operating cash flow in the past year.
Each year in the past 5 years ICLR has been profitable.
ICLR had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
ICLR has a Return On Assets of 3.60%. This is in the better half of the industry: ICLR outperforms 74.58% of its industry peers.
ICLR's Return On Equity of 6.63% is fine compared to the rest of the industry. ICLR outperforms 76.27% of its industry peers.
ICLR has a Return On Invested Capital of 5.83%. This is in the better half of the industry: ICLR outperforms 74.58% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for ICLR is significantly below the industry average of 9.62%.
The 3 year average ROIC (4.59%) for ICLR is below the current ROIC(5.83%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.6% | ||
| ROE | 6.63% | ||
| ROIC | 5.83% |
ROA(3y)2.48%
ROA(5y)5.99%
ROE(3y)4.82%
ROE(5y)11.11%
ROIC(3y)4.59%
ROIC(5y)9.41%
1.3 Margins
The Profit Margin of ICLR (7.54%) is better than 76.27% of its industry peers.
In the last couple of years the Profit Margin of ICLR has declined.
With a decent Operating Margin value of 12.88%, ICLR is doing good in the industry, outperforming 71.19% of the companies in the same industry.
In the last couple of years the Operating Margin of ICLR has declined.
The Gross Margin of ICLR (29.66%) is worse than 74.58% of its industry peers.
ICLR's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 12.88% | ||
| PM (TTM) | 7.54% | ||
| GM | 29.66% |
OM growth 3Y-4.19%
OM growth 5Y-2.83%
PM growth 3Y-14.06%
PM growth 5Y-9.51%
GM growth 3Y0.39%
GM growth 5Y-0.2%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), ICLR is destroying value.
The number of shares outstanding for ICLR has been increased compared to 1 year ago.
Compared to 5 years ago, ICLR has more shares outstanding
The debt/assets ratio for ICLR has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 2.84 indicates that ICLR is not a great score, but indicates only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.84, ICLR is in line with its industry, outperforming 57.63% of the companies in the same industry.
The Debt to FCF ratio of ICLR is 3.70, which is a good value as it means it would take ICLR, 3.70 years of fcf income to pay off all of its debts.
ICLR's Debt to FCF ratio of 3.70 is amongst the best of the industry. ICLR outperforms 83.05% of its industry peers.
A Debt/Equity ratio of 0.40 indicates that ICLR is not too dependend on debt financing.
ICLR has a worse Debt to Equity ratio (0.40) than 62.71% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.4 | ||
| Debt/FCF | 3.7 | ||
| Altman-Z | 2.84 |
ROIC/WACC0.63
WACC9.26%
2.3 Liquidity
ICLR has a Current Ratio of 1.21. This is a normal value and indicates that ICLR is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of ICLR (1.21) is worse than 91.53% of its industry peers.
A Quick Ratio of 1.21 indicates that ICLR should not have too much problems paying its short term obligations.
ICLR's Quick ratio of 1.21 is on the low side compared to the rest of the industry. ICLR is outperformed by 81.36% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.21 | ||
| Quick Ratio | 1.21 |
3. Growth
3.1 Past
ICLR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 8.68%, which is quite good.
The Earnings Per Share has been growing by 15.96% on average over the past years. This is quite good.
The Revenue has been growing slightly by 4.89% in the past year.
Measured over the past years, ICLR shows a very strong growth in Revenue. The Revenue has been growing by 25.62% on average per year.
EPS 1Y (TTM)8.68%
EPS 3Y25.12%
EPS 5Y15.96%
EPS growth Q2Q10.54%
Revenue 1Y (TTM)4.89%
Revenue growth 3Y42.65%
Revenue growth 5Y25.62%
Revenue growth Q2Q5.31%
3.2 Future
The Earnings Per Share is expected to grow by 8.76% on average over the next years. This is quite good.
ICLR is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.18% yearly.
EPS Next Y19.37%
EPS Next 2Y16.7%
EPS Next 3Y15.13%
EPS Next 5Y8.76%
Revenue Next Year6.02%
Revenue Next 2Y6.66%
Revenue Next 3Y6.81%
Revenue Next 5Y7.18%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 24.14, which indicates a rather expensive current valuation of ICLR.
Compared to the rest of the industry, the Price/Earnings ratio of ICLR indicates a rather cheap valuation: ICLR is cheaper than 89.83% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 24.92, ICLR is valued at the same level.
The Price/Forward Earnings ratio is 20.23, which indicates a rather expensive current valuation of ICLR.
94.92% of the companies in the same industry are more expensive than ICLR, based on the Price/Forward Earnings ratio.
ICLR is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 21.49, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.14 | ||
| Fwd PE | 20.23 |
4.2 Price Multiples
ICLR's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. ICLR is cheaper than 88.14% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, ICLR is valued cheaply inside the industry as 91.53% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 24.93 | ||
| EV/EBITDA | 17.25 |
4.3 Compensation for Growth
ICLR's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
The decent profitability rating of ICLR may justify a higher PE ratio.
A more expensive valuation may be justified as ICLR's earnings are expected to grow with 15.13% in the coming years.
PEG (NY)1.25
PEG (5Y)1.51
EPS Next 2Y16.7%
EPS Next 3Y15.13%
5. Dividend
5.1 Amount
No dividends for ICLR!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ICON PLC
NASDAQ:ICLR (4/26/2024, 7:00:02 PM)
After market: 308.31 0 (0%)308.31
+8.23 (+2.74%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap25.44B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.14 | ||
| Fwd PE | 20.23 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)1.25
PEG (5Y)1.51
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.6% | ||
| ROE | 6.63% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 12.88% | ||
| PM (TTM) | 7.54% | ||
| GM | 29.66% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.48
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.4 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.21 | ||
| Quick Ratio | 1.21 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)8.68%
EPS 3Y25.12%
EPS 5Y
EPS growth Q2Q
EPS Next Y19.37%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)4.89%
Revenue growth 3Y42.65%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y